Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Zilucoplan in Subjects With Immune-Mediated Necrotizing Myopathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of IMNM (Immune-Mediated Necrotizing Myopathy)~* Positive serology for anti-3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMGCR) or anti-signal recognition particle (SRP) autoantibodies~* Clinical evidence of weakness (≤ grade 4 out of 5) on manual muscle testing in at least one proximal limb muscle group~* Creatine kinase (CK) of \>1000 U/L at Screening~* No change in corticosteroid dose for at least 30 days prior to Baseline or anticipated to occur during the first 8-weeks on study~* No changes in immunosuppressive therapy, including dose, for at least 30 days prior to Baseline or anticipated to occur during the first 8-weeks on study~Exclusion Criteria:~* History of meningococcal disease~* Current or recent systemic infection within 2 weeks prior to Screening or infection requiring intravenous (IV) antibiotics within 4 weeks prior to Screening~* Recent initiation of intravenous immunoglobulin (IVIG) (i.e., first cycle administered less than 90 days prior to Baseline)~* Rituximab use within 90 days prior to Baseline or anticipated to occur during study~* Statin use within 30 days prior to Baseline or anticipated to occur during study~* Plasma exchange within 4 weeks prior to Baseline or expected to occur during the 8-week Treatment Period

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 0.3 mg/kg zilucoplan (Type: EXPERIMENTAL): Daily subcutaneous (SC) injection
- Placebo (Type: PLACEBO_COMPARATOR): Daily subcutaneous (SC) injection

Based on this trial design, predict the completion outcome and termination type (if applicable).